Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.

Peter Lin Corey Lourenco Jennifer Cruickshank Luis Palomero Jenna E van Leeuwen Amy H Y Tong Katherine Chan Samah El Ghamrasni Miguel Angel Pujana David W Cescon Jason Moffat Linda Z Penn

Published in: Cancer research (2023)

CRISPR screening reveals topoisomerase 1 as an immediately actionable vulnerability in cancers harboring MYC as a driver oncoprotein that can be targeted with clinically approved inhibitors.

Keyphrases

transcription factor
papillary thyroid
crispr cas
genome wide
climate change
genome editing
squamous cell
childhood cancer
cancer therapy
squamous cell carcinoma
young adults
dna methylation
drug delivery
dna binding